Oridonin
Based on 27 publication(s) in Google Scholar
Oridonin (NSC-250682), a diterpenoid isolated from Rabdosia rubescens, acts as an inhibitor of AKT, with IC50s of 8.4 and 8.9 μM for AKT1 and AKT2; Oridonin possesses anti-tumor, anti-bacterial and anti-inflammatory effects.
For research use only. We do not sell to patients.
- Purity: 99.89%
- CAS No.: 28957-04-2
- Formula: C20H28O6
- Molecular Weight:364.43
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) Oridonin
More- Adv Funct Mater. 2023 Dec 22.
- Nat Commun. 2025 May 27;16(1):4887. [Abstract]
- Acta Pharmacol Sin. 2023 Apr;44(4):726-740. [Abstract]
- Phytomedicine. 2024 Apr:126:155426. [Abstract]
- Phytomedicine. 2024 Jan:122:155159. [Abstract]
- Phytother Res. 2021 May;35(5):2624-2638. [Abstract]
- Cell Mol Life Sci. 2025 May 28;82(1):218. [Abstract]
- Cell Mol Life Sci. 2021 Dec 31;79(1):27. [Abstract]
- Anal Chim Acta. 2021 Jun 22:1165:338478. [Abstract]
- Biochem Pharmacol. 2025 Apr 16:116953. [Abstract]
- Biochem Pharmacol. 2020 Jul;177:113998. [Abstract]
- Drug Des Devel Ther. 2022 Dec 20:16:4311-4323. [Abstract]
- Eur J Pharmacol. 2026 Mar 28:1019:178664. [Abstract]
- Eur J Pharmacol. 2026 Feb 15:1015:178559. [Abstract]
- Int Immunopharmacol. 2021 Dec;101(Pt B):108290. [Abstract]
- Drug Dev Res. 2024 Sep;85(6):e22251. [Abstract]
- Calcif Tissue Int. 2023 Jun;112(6):704-715. [Abstract]
- Biophys J. 2026 Mar 3;125(5):1247-1256. [Abstract]
- Front Biosci (Landmark Ed). 2023 Sep 6;28(9):195. [Abstract]
- Mol Biol Rep. 2026 May 7;53(1):724.
- Dev Comp Immunol. 2025 Jan 21:105324. [Abstract]
- Dev Comp Immunol. 2021 Jun:119:104042. [Abstract]
- Biomed Res Int. 2021 Jul 5:2021:4340950. [Abstract]
- Biochem Biophys Res Commun. 2025 Oct 22:788:152845. [Abstract]
- Biochem Biophys Res Commun. 2022 Nov 12:629:152-158. [Abstract]
- Res Sq. 2024 Oct 14.
- Research Square Print. September 30th, 2022.
-
ELISA
-
WB
-
In Vivo Efficacy Study
-
WB
-
Bio/Physico-chemical Assay
Biological Activity
|
Akt1 8.4 μM (IC50) |
Akt2 8.9 μM (IC50) |
MDM2 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>10 μM
Compound: 20
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
| A549 | IC50 |
>10 μM
Compound: 18
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 20521771] |
| A549 | IC50 |
10.4 μM
Compound: 1
|
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
[PMID: 27089099] |
| A549 | IC50 |
13.45 μM
Compound: Oridonin
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31494472] |
| A549 | IC50 |
17.8 μM
Compound: 1
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31202992] |
| A549 | IC50 |
18.15 μM
Compound: 1
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30921757] |
| A549 | IC50 |
18.7 μM
Compound: Oridonin
|
Antiproliferative activity against human A549 cells by MTT assay
Antiproliferative activity against human A549 cells by MTT assay
|
[PMID: 26115572] |
| A549 | IC50 |
25.4 μM
Compound: Oridonin
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 30193221] |
| A549 | IC50 |
26.15 μM
Compound: Oridonin
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 22483090] |
| A549 | IC50 |
27.24 μM
Compound: 1
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 18644718] |
| A549 | IC50 |
30.4 μM
Compound: 1; ORI
|
Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 cells
Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 cells
|
[PMID: 31200238] |
| A549 | IC50 |
7.2 μM
Compound: 4
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 25590529] |
| B16 | IC50 |
24.89 μM
Compound: 1
|
Antiproliferative activity against mouse B16 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against mouse B16 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| B16 | IC50 |
26.15 μM
Compound: 1
|
Cytotoxicity against mouse B16 cells by MTT assay
Cytotoxicity against mouse B16 cells by MTT assay
|
[PMID: 18644718] |
| Bel-7402 | IC50 |
>10 μM
Compound: 1
|
Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
|
[PMID: 28901767] |
| Bel-7402 | IC50 |
39.8 μM
Compound: 1
|
Cytotoxicity against human BEL-7402 cells by MTT assay
Cytotoxicity against human BEL-7402 cells by MTT assay
|
[PMID: 18644718] |
| Bel-7402 | IC50 |
5.41 μM
Compound: 1
|
Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
|
[PMID: 28165738] |
| Bel-7402 | IC50 |
7.12 μM
Compound: 1
|
Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 27158140] |
| Bel-7402 | IC50 |
7.36 μM
Compound: 1
|
Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
|
[PMID: 29407983] |
| Bel-7402 | IC50 |
7.48 μM
Compound: 1
|
Anticancer activity against human Bel7402 cells assessed as growth inhibition by MTT assay
Anticancer activity against human Bel7402 cells assessed as growth inhibition by MTT assay
|
[PMID: 25050168] |
| Bel-7402 | IC50 |
7.48 μM
Compound: 1
|
Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 25050168] |
| Bel-7402 | IC50 |
7.48 μM
Compound: 9
|
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
|
[PMID: 23644204] |
| Bel-7402 | IC50 |
7.48 μM
Compound: Oridonin
|
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
|
[PMID: 22483090] |
| Bel-7402 | IC50 |
7.48 μM
Compound: Oridonin
|
Antiproliferative activity against human Bel7402 cells assessed as growth inhibition by MTT assay
Antiproliferative activity against human Bel7402 cells assessed as growth inhibition by MTT assay
|
[PMID: 23274570] |
| Bel-7402 | IC50 |
7.56 μM
Compound: 7
|
Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay
|
[PMID: 27491707] |
| Bel-7402 | IC50 |
7.85 μM
Compound: 1
|
Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30921757] |
| Bel-7402 | IC50 |
8.31 μM
Compound: 1
|
Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31202992] |
| Bel-7402 | IC50 |
9.59 μM
Compound: Oridonin
|
Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 30981113] |
| Bel7402/5-FU | IC50 |
10.51 μM
Compound: 1
|
Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by MTT assay
Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by MTT assay
|
[PMID: 29407983] |
| BEL-7404 tumor cell line | IC50 |
17.92 μM
Compound: 1
|
Antiproliferative activity against human Bel7404 cells after 48 hrs by MTT assay
Antiproliferative activity against human Bel7404 cells after 48 hrs by MTT assay
|
[PMID: 28165738] |
| DU-4475 | IC50 |
16.95 μM
Compound: 1
|
Antiproliferative activity against human DU4475 cells after 72 hrs by MTT assay
Antiproliferative activity against human DU4475 cells after 72 hrs by MTT assay
|
[PMID: 32610904] |
| EC9706 | IC50 |
38.42 μM
Compound: Oridonin
|
Antiproliferative activity against human EC9706 cells after 48 hrs by MTT assay
Antiproliferative activity against human EC9706 cells after 48 hrs by MTT assay
|
[PMID: 30143365] |
| H22 | IC50 |
4.88 μM
Compound: 1
|
Antiproliferative activity against mouse H22 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against mouse H22 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35121201] |
| HCC1806 | IC50 |
21.74 μM
Compound: 1
|
Antiproliferative activity against human HCC1806 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCC1806 cells after 72 hrs by MTT assay
|
[PMID: 32610904] |
| HCC1937 | IC50 |
8.27 μM
Compound: 1
|
Antiproliferative activity against human HCC1937 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCC1937 cells after 72 hrs by MTT assay
|
[PMID: 32610904] |
| HCT-116 | IC50 |
11.73 μM
Compound: 1
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| HCT-116 | IC50 |
6.84 μM
Compound: Oridonin
|
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 30981113] |
| HCT-116 | IC50 |
6.84 μM
Compound: Oridonin
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by MTS assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by MTS assay
|
[PMID: 38107170] |
| HEK-293T | IC50 |
>5 μM
Compound: 23
|
Cytotoxicity against human 293T cells assessed as cell viability by dual-luciferase reporter assay
Cytotoxicity against human 293T cells assessed as cell viability by dual-luciferase reporter assay
|
[PMID: 21393004] |
| HeLa | IC50 |
17.28 μM
Compound: 1
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35121201] |
| HeLa | IC50 |
17.8 μM
Compound: 1
|
Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
[PMID: 27089099] |
| HeLa | IC50 |
32.7 μM
Compound: Oridonin
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 22483090] |
| HEp-2 | EC50 |
37.1 μM
Compound: 1
|
Anticancer activity against human Hep2 cells measured after 24 hrs by MTT assay
Anticancer activity against human Hep2 cells measured after 24 hrs by MTT assay
|
[PMID: 27344488] |
| HEp-2 | IC50 |
37.1 μM
Compound: 1
|
Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay
Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay
|
[PMID: 20496901] |
| HepG2 | IC50 |
15.2 μM
Compound: 1
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
[PMID: 27089099] |
| HepG2 | IC50 |
3.66 μM
Compound: Oridonin
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 21144747] |
| HepG2 | IC50 |
8.12 μM
Compound: 1; ORI
|
Antiproliferative activity against human HepG2 cells incubated for 72 hrs by CCK8 cells
Antiproliferative activity against human HepG2 cells incubated for 72 hrs by CCK8 cells
|
[PMID: 31200238] |
| HepG2 | IC50 |
8.95 μM
Compound: 1
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| HGC-27 | IC50 |
32.03 μM
Compound: Oridonin
|
Antiproliferative activity against human HGC27 cells after 48 hrs by MTT assay
Antiproliferative activity against human HGC27 cells after 48 hrs by MTT assay
|
[PMID: 30143365] |
| HL-60 | IC50 |
14.3 μM
Compound: 1
|
Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
|
[PMID: 29407983] |
| HL-60 | IC50 |
2.5 μM
Compound: 20
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
| HL-60 | IC50 |
3.9 μM
Compound: 18
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 20521771] |
| HL-60 | IC50 |
32.76 μM
Compound: 1
|
Cytotoxicity against human HL60 cells by MTT assay
Cytotoxicity against human HL60 cells by MTT assay
|
[PMID: 18644718] |
| HL-60 | IC50 |
7.2 μM
Compound: 4
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 25590529] |
| HL-60 | IC50 |
9.46 μM
Compound: 1
|
Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30921757] |
| HMEC | IC50 |
5.6 μM
Compound: 1
|
Growth inhibition of human HMEC cells after 48 hrs
Growth inhibition of human HMEC cells after 48 hrs
|
[PMID: 24128046] |
| HMEC-1 | IC50 |
>4 μg/mL
Compound: 2
|
Cytotoxicity against HMEC1 cells by resazurin assay
Cytotoxicity against HMEC1 cells by resazurin assay
|
[PMID: 14738375] |
| HSC-T6 | EC50 |
7 μM
Compound: 1
|
Anticancer activity against rat HSC-T6 cells measured after 48 hrs by alamar blue assay
Anticancer activity against rat HSC-T6 cells measured after 48 hrs by alamar blue assay
|
[PMID: 27344488] |
| Jurkat | EC50 |
1.2 μM
Compound: 1
|
Anticancer activity against human Jurkat cells measured after 48 hrs by trypan blue assay
Anticancer activity against human Jurkat cells measured after 48 hrs by trypan blue assay
|
[PMID: 27344488] |
| K562 | EC50 |
14.6 μM
Compound: 1
|
Anticancer activity against human K562 cells measured after 24 hrs by MTT assay
Anticancer activity against human K562 cells measured after 24 hrs by MTT assay
|
[PMID: 27344488] |
| K562 | EC50 |
4.76 μM
Compound: 1
|
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 27344488] |
| K562 | IC50 |
4.25 μM
Compound: 1
|
Antiproliferative activity against human K562 cells assessed as reduction in cell growth after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as reduction in cell growth after 72 hrs by MTT assay
|
[PMID: 36037626] |
| K562 | IC50 |
4.32 μM
Compound: 1
|
Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35121201] |
| K562 | IC50 |
4.33 μM
Compound: 1
|
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 28165738] |
| K562 | IC50 |
4.57 μM
Compound: 1
|
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| K562 | IC50 |
4.59 μM
Compound: 7
|
Antiproliferative activity against human K562 cells after 24 hrs by MTT assay
Antiproliferative activity against human K562 cells after 24 hrs by MTT assay
|
[PMID: 27491707] |
| K562 | IC50 |
4.64 μM
Compound: 1
|
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30921757] |
| K562 | IC50 |
4.76 μM
Compound: 1
|
Antiproliferative activity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 25050168] |
| K562 | IC50 |
4.76 μM
Compound: 1
|
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27089099] |
| K562 | IC50 |
4.76 μM
Compound: 9
|
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 23644204] |
| K562 | IC50 |
4.76 μM
Compound: Oridonin
|
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 22483090] |
| K562 | IC50 |
4.76 μM
Compound: Oridonin
|
Antiproliferative activity against human K562 cells assessed as growth inhibition by MTT assay
Antiproliferative activity against human K562 cells assessed as growth inhibition by MTT assay
|
[PMID: 23274570] |
| K562 | IC50 |
4.79 μM
Compound: 1
|
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31202992] |
| K562 | IC50 |
5.1 μM
Compound: 1
|
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 28901767] |
| K562/Adr | EC50 |
<40 μM
Compound: 1
|
Anticancer activity against human K562/ADR cells measured after 24 hrs by MTT assay
Anticancer activity against human K562/ADR cells measured after 24 hrs by MTT assay
|
[PMID: 27344488] |
| Kasumi 1 | EC50 |
1.33 μM
Compound: 1
|
Anticancer activity against human Kasumi-1 cells measured after 48 hrs by CCK8 assay
Anticancer activity against human Kasumi-1 cells measured after 48 hrs by CCK8 assay
|
[PMID: 27344488] |
| KB 3-1 | IC50 |
13.24 μM
Compound: 1
|
Antiproliferative activity against human KB-3-1 cells after 48 hrs by MTT assay
Antiproliferative activity against human KB-3-1 cells after 48 hrs by MTT assay
|
[PMID: 28165738] |
| L02 | IC50 |
17.47 μM
Compound: 1; ORI
|
Cytotoxicity against human LO2 cells incubated for 72 hrs by CCK8 cells
Cytotoxicity against human LO2 cells incubated for 72 hrs by CCK8 cells
|
[PMID: 31200238] |
| L02 | IC50 |
17.78 μM
Compound: 1
|
Cytotoxicity against human L02 cells by MTT assay
Cytotoxicity against human L02 cells by MTT assay
|
[PMID: 25050168] |
| L02 | IC50 |
18.68 μM
Compound: 1
|
Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31202992] |
| L02 | IC50 |
18.94 μM
Compound: 1
|
Antiproliferative activity against human LO2 cells after 72 hrs by MTT assay
Antiproliferative activity against human LO2 cells after 72 hrs by MTT assay
|
[PMID: 29407983] |
| L02 | IC50 |
19.53 μM
Compound: 1
|
Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30921757] |
| L02 | IC50 |
21.59 μM
Compound: 1
|
Cytotoxicity against human L02 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| L02 | IC50 |
25.01 μM
Compound: 1
|
Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay
|
[PMID: 36037626] |
| L02 | IC50 |
34.32 μM
Compound: 1
|
Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35121201] |
| L02 | IC50 |
38.2 μM
Compound: Ori
|
Cytotoxicity against human L-02 cells incubated for 24 hrs by MTT assay
Cytotoxicity against human L-02 cells incubated for 24 hrs by MTT assay
|
[PMID: 34506712] |
| L02 | IC50 |
42.25 μM
Compound: Oridonin
|
Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 35428012] |
| L02 | IC50 |
6.97 μM
Compound: Oridonin
|
Cytotoxicity in human L02 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity in human L02 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 30981113] |
| LNCaP | EC50 |
25 μM
Compound: 1
|
Anticancer activity against human LNCAP cells measured after 48 hrs by CCK8 assay
Anticancer activity against human LNCAP cells measured after 48 hrs by CCK8 assay
|
[PMID: 27344488] |
| MCF7 | EC50 |
4.4 μM
Compound: 1
|
Antiproliferative activity against human ER-positive MCF7 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human ER-positive MCF7 cells measured after 48 hrs by MTT assay
|
[PMID: 27344488] |
| MCF7 | EC50 |
6.6 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
|
[PMID: 27344488] |
| MCF7 | IC50 |
>10 μM
Compound: 20
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
| MCF7 | IC50 |
11.11 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35121201] |
| MCF7 | IC50 |
13.85 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| MCF7 | IC50 |
14.6 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 25050168] |
| MCF7 | IC50 |
14.6 μM
Compound: Oridonin
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 22483090] |
| MCF7 | IC50 |
17.56 μM
Compound: Oridonin
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 30981113] |
| MCF7 | IC50 |
17.89 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 28165738] |
| MCF7 | IC50 |
21.97 μM
Compound: Oridonin
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31494472] |
| MCF7 | IC50 |
21.97 μM
Compound: Oridonin
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
[PMID: 32883640] |
| MCF7 | IC50 |
4.36 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 24128046] |
| MCF7 | IC50 |
6.6 μM
Compound: 126
|
Antiproliferative activity against ER-positive human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against ER-positive human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 35033884] |
| MCF7 | IC50 |
6.72 μM
Compound: 13
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 29528645] |
| MCF7 | IC50 |
64.3 μM
Compound: Oridonin
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 30193221] |
| MCF7 | IC50 |
7.2 μM
Compound: 4
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 25590529] |
| MCF7 | IC50 |
74.18 μM
Compound: Oridonin
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 30143365] |
| MCF7 | IC50 |
9.1 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 28901767] |
| MDA-MB-231 | EC50 |
28 μM
Compound: 1
|
Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
|
[PMID: 27344488] |
| MDA-MB-231 | EC50 |
29.4 μM
Compound: Oridonin
|
Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
|
[PMID: 30981113] |
| MDA-MB-231 | EC50 |
29.4 μM
Compound: 1
|
Antiproliferative activity against human MDA-MB-231 cells
Antiproliferative activity against human MDA-MB-231 cells
|
[PMID: 27344488] |
| MDA-MB-231 | IC50 |
11.62 μM
Compound: 1
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35121201] |
| MDA-MB-231 | IC50 |
11.68 μM
Compound: 1
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth after 72 hrs by MTT assay
|
[PMID: 36037626] |
| MDA-MB-231 | IC50 |
17.92 μM
Compound: 1
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
|
[PMID: 32610904] |
| MDA-MB-231 | IC50 |
2.38 μM
Compound: Oridonin
|
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 21144747] |
| MDA-MB-231 | IC50 |
28 μM
Compound: 1
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 24128046] |
| MDA-MB-231 | IC50 |
29.4 μM
Compound: 13
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
|
[PMID: 29528645] |
| MDA-MB-453 | IC50 |
6.67 μM
Compound: 1
|
Antiproliferative activity against human MDA-MB-453 cells after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-453 cells after 72 hrs by MTT assay
|
[PMID: 32610904] |
| MDA-MB-468 | EC50 |
5.3 μM
Compound: 1
|
Antiproliferative activity against human ER-triple negative MDA-MB-468 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human ER-triple negative MDA-MB-468 cells measured after 48 hrs by MTT assay
|
[PMID: 27344488] |
| MDA-MB-468 | IC50 |
17.28 μM
Compound: 1
|
Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by MTT assay
|
[PMID: 32610904] |
| MGC-803 | EC50 |
5.69 μM
Compound: 1
|
Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
|
[PMID: 27344488] |
| MGC-803 | IC50 |
14.13 μM
Compound: Oridonin
|
Antiproliferative activity against human MGC803 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human MGC803 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31494472] |
| MGC-803 | IC50 |
14.13 μM
Compound: Oridonin
|
Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
[PMID: 32883640] |
| MGC-803 | IC50 |
15.11 μM
Compound: 1
|
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35121201] |
| MGC-803 | IC50 |
3.57 μM
Compound: Oridonin
|
Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
|
[PMID: 21144747] |
| MGC-803 | IC50 |
33.1 μM
Compound: Oridonin
|
Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
|
[PMID: 30143365] |
| MGC-803 | IC50 |
34.3 μM
Compound: Oridonin
|
Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
|
[PMID: 30193221] |
| MGC-803 | IC50 |
4.5 μM
Compound: 1
|
Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
|
[PMID: 28901767] |
| MGC-803 | IC50 |
5.47 μM
Compound: 7
|
Antiproliferative activity against human MGC803 cells after 24 hrs by MTT assay
Antiproliferative activity against human MGC803 cells after 24 hrs by MTT assay
|
[PMID: 27491707] |
| MGC-803 | IC50 |
5.69 μM
Compound: 1
|
Antiproliferative activity against human MGC803 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human MGC803 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 25050168] |
| MGC-803 | IC50 |
5.69 μM
Compound: 9
|
Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
|
[PMID: 23644204] |
| MGC-803 | IC50 |
5.69 μM
Compound: Oridonin
|
Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
|
[PMID: 22483090] |
| MGC-803 | IC50 |
5.69 μM
Compound: Oridonin
|
Antiproliferative activity against human MGC803 cells assessed as growth inhibition by MTT assay
Antiproliferative activity against human MGC803 cells assessed as growth inhibition by MTT assay
|
[PMID: 23274570] |
| MGC-803 | IC50 |
9.06 μM
Compound: 1
|
Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
|
[PMID: 28165738] |
| MT2 | EC50 |
1.2 μM
Compound: 1
|
Anticancer activity against human MT2 cells measured after 48 hrs by trypan blue assay
Anticancer activity against human MT2 cells measured after 48 hrs by trypan blue assay
|
[PMID: 27344488] |
| NCI/ADR-RES | EC50 |
34.8 μM
Compound: 1
|
Antiproliferative activity against human MCF7/ADR cells measured after 48 hrs by MTT assay
Antiproliferative activity against human MCF7/ADR cells measured after 48 hrs by MTT assay
|
[PMID: 27344488] |
| NCI/ADR-RES | IC50 |
>30 μM
Compound: 1
|
Growth inhibition of human MCF7/ADR cells after 48 hrs
Growth inhibition of human MCF7/ADR cells after 48 hrs
|
[PMID: 24128046] |
| NCI/ADR-RES | IC50 |
26.18 μM
Compound: 1
|
Antiproliferative activity against human MCF7/ADR cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7/ADR cells after 72 hrs by MTT assay
|
[PMID: 32610904] |
| NCI-H460 | IC50 |
17.14 μM
Compound: 1
|
Anticancer activity against human NCI-H460 cells by MTT assay
Anticancer activity against human NCI-H460 cells by MTT assay
|
[PMID: 25050168] |
| NCI-H460 | IC50 |
20.51 μM
Compound: 1
|
Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay
Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay
|
[PMID: 28165738] |
| PANC-1 | IC50 |
>10 μM
Compound: 18
|
Growth inhibition of human PANC1 cells after 48 hrs by SRB assay
Growth inhibition of human PANC1 cells after 48 hrs by SRB assay
|
[PMID: 20521771] |
| Panel NCI-60 (60 carcinoma cell lines) | GI50 |
453 nM
Compound: Oridonin
|
Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program
Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program
|
[PMID: 15743190] |
| PBMC | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31202992] |
| PBMC | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human PBMC cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human PBMC cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| PC-3 | EC50 |
25 μM
Compound: 1
|
Anticancer activity against human PC3 cells measured after 48 hrs by CCK8 assay
Anticancer activity against human PC3 cells measured after 48 hrs by CCK8 assay
|
[PMID: 27344488] |
| PC-3 | IC50 |
10.07 μM
Compound: 1
|
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30921757] |
| PC-3 | IC50 |
10.97 μM
Compound: 1
|
Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 29407983] |
| PC-3 | IC50 |
27.55 μM
Compound: Oridonin
|
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 30143365] |
| PC-3 | IC50 |
43.9 μM
Compound: Oridonin
|
Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 30193221] |
| PLC-PRF-5 | IC50 |
7.41 μM
Compound: 1; ORI
|
Antiproliferative activity against human PLC/PRF/5 cells incubated for 72 hrs by CCK8 cells
Antiproliferative activity against human PLC/PRF/5 cells incubated for 72 hrs by CCK8 cells
|
[PMID: 31200238] |
| RAW264.7 | IC50 |
5.2 μM
Compound: 20
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by Griess method
|
[PMID: 23819871] |
| RPMI-8226 | EC50 |
1.2 μM
Compound: 1
|
Anticancer activity against human RPMI8226 cells measured after 48 hrs by trypan blue assay
Anticancer activity against human RPMI8226 cells measured after 48 hrs by trypan blue assay
|
[PMID: 27344488] |
| RPMI-8226 | IC50 |
9.25 μM
Compound: 1; ORI
|
Antiproliferative activity against human RPMI8226 cells incubated for 72 hrs by CCK8 cells
Antiproliferative activity against human RPMI8226 cells incubated for 72 hrs by CCK8 cells
|
[PMID: 31200238] |
| SGC-7901 | IC50 |
7.13 μM
Compound: 1
|
Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30921757] |
| SGC-7901 | IC50 |
7.87 μM
Compound: 1
|
Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31202992] |
| SK-BR-3 | IC50 |
>10 μM
Compound: 18
|
Cytotoxicity against human SK-BR-3 cells after 48 hrs by MTT assay
Cytotoxicity against human SK-BR-3 cells after 48 hrs by MTT assay
|
[PMID: 20521771] |
| SK-BR-3 | IC50 |
8.49 μM
Compound: 1
|
Antiproliferative activity against human SK-BR-3 cells after 72 hrs by MTT assay
Antiproliferative activity against human SK-BR-3 cells after 72 hrs by MTT assay
|
[PMID: 32610904] |
| SMMC-7721 | IC50 |
>10 μM
Compound: 20
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
| SMMC-7721 | IC50 |
>10 μM
Compound: 18
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
|
[PMID: 20521771] |
| SMMC-7721 | IC50 |
12.57 μM
Compound: 1
|
Antiproliferative activity against human SMMC-7221 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human SMMC-7221 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35121201] |
| SMMC-7721 | IC50 |
14.41 μM
Compound: 1
|
Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell growth after 72 hrs by MTT assay
Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell growth after 72 hrs by MTT assay
|
[PMID: 36037626] |
| SMMC-7721 | IC50 |
30.1 μM
Compound: Oridonin
|
Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
|
[PMID: 30193221] |
| SMMC-7721 | IC50 |
53.95 μM
Compound: Oridonin
|
Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
|
[PMID: 30143365] |
| SMMC-7721 | IC50 |
7.2 μM
Compound: 4
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
|
[PMID: 25590529] |
| SW480 | EC50 |
20.8 μM
Compound: 1
|
Anticancer activity against human SW480 cells measured after 24 hrs by MTT assay
Anticancer activity against human SW480 cells measured after 24 hrs by MTT assay
|
[PMID: 27344488] |
| SW480 | IC50 |
>10 μM
Compound: 20
|
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
| SW480 | IC50 |
10.59 μM
Compound: 1
|
Antiproliferative activity against human SW480 cells assessed as reduction in cell growth after 72 hrs by MTT assay
Antiproliferative activity against human SW480 cells assessed as reduction in cell growth after 72 hrs by MTT assay
|
[PMID: 36037626] |
| SW480 | IC50 |
11.63 μM
Compound: 1
|
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35121201] |
| SW480 | IC50 |
31.42 μM
Compound: 1
|
Cytotoxicity against human SW480 cells by MTT assay
Cytotoxicity against human SW480 cells by MTT assay
|
[PMID: 18644718] |
| SW480 | IC50 |
7.2 μM
Compound: 4
|
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
|
[PMID: 25590529] |
| SW-620 | EC50 |
20.8 μM
Compound: 1
|
Anticancer activity against human SW620 cells measured after 24 hrs by MTT assay
Anticancer activity against human SW620 cells measured after 24 hrs by MTT assay
|
[PMID: 27344488] |
| SW-620 | IC50 |
4.67 μM
Compound: 1
|
Anticancer activity against ABCB1-overexpressing human SW620/AD300 cells by MTT assay
Anticancer activity against ABCB1-overexpressing human SW620/AD300 cells by MTT assay
|
[PMID: 25050168] |
| SW-620 | IC50 |
6.26 μM
Compound: 1
|
Anticancer activity against human SW620 cells by MTT assay
Anticancer activity against human SW620 cells by MTT assay
|
[PMID: 25050168] |
| T47D | IC50 |
7.56 μM
Compound: 1
|
Antiproliferative activity against human T47D cells after 72 hrs by MTT assay
Antiproliferative activity against human T47D cells after 72 hrs by MTT assay
|
[PMID: 32610904] |
| TE-1 | IC50 |
12.73 μM
Compound: Oridonin
|
Antiproliferative activity against human TE1 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human TE1 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31494472] |
| TE-1 | IC50 |
12.73 μM
Compound: Oridonin
|
Antiproliferative activity against human TE-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
Antiproliferative activity against human TE-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
[PMID: 32883640] |
| THP-1 | CC50 |
19.8 μM
Compound: Oridonin
|
Cytotoxicity against human THP-1 cells by CCK-8 method
Cytotoxicity against human THP-1 cells by CCK-8 method
|
[PMID: 38244941] |
| U-266 | EC50 |
1.2 μM
Compound: 1
|
Anticancer activity against human U266 cells measured after 48 hrs by trypan blue assay
Anticancer activity against human U266 cells measured after 48 hrs by trypan blue assay
|
[PMID: 27344488] |
| U-87MG ATCC | IC50 |
14.05 μM
Compound: 1
|
Antiproliferative activity against human U-87 MG cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human U-87 MG cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35121201] |
Oridonin is an ATP-competitive inhibitor of AKT with IC50s of 8.4 and 8.9 μM for AKT1 and AKT2, respectively. Oridonin (5, 10 or 20 μM) obviously inhibits the growth of KYSE70, KYSE410 and KYSE450 ESCC cells via targeting AKT1/2. Oridonin (10 or 20 μM) causes G2/M phase cell cycle arrest in KYSE70, KYSE410 and KYSE450 cells, and induces apoptosis in these three cell lines at 20 μM. In addition, Oridonin (5, 10 or 20 μM) in combination with cisplatin or 5-FU enhances the inhibition of esophageal squamous cell carcinoma (ESCC) cell growth[1]. Oridonin (0.1 and 1 μM) preferentially suppresses AKT/mTOR signaling. Oridonin (1 μM) also selectively suppresses growth of breast cancer cells with hyperactivation of AKT signaling[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 28957-04-2
-
Appearance Solid
-
Molecular Weight 364.43
-
Formula C20H28O6
-
Color White to off-white
-
SMILES
O[C@@H]1[C@]2(CO3)[C@@]([C@H](O)[C@]3(O)[C@]45[C@@]2([H])CC[C@](C(C5=O)=C)([H])[C@@]4([H])O)([H])C(C)(C)CC1
-
Synonyms
NSC-250682; Isodonol
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (27)
-
Journal Impact Factor
-
Most Recent
-
-
Nat Commun
Clustering of NLRP3 induced by membrane or protein scaffolds promotes inflammasome assembly. [Abstract]2025 May 27;16(1):4887. PMID: 40425567
Oridonin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 27;16(1):4887. [Abstract]
Oridonin (0.5-2.5 µM; 11 h). NLRP3-KO iBMDMs were stimulated with LPS and Dox after a 30-min pre-incubation with inhibitors or DMSO, except for Ctrl, where only LPS was added. Measurements of IL-1β were normalized to “LPS/Dox”- treated WTR258W.
-
Acta Pharmacol Sin
Oridonin ameliorates caspase-9-mediated brain neuronal apoptosis in mouse with ischemic stroke by inhibiting RIPK3-mediated mitophagy. [Abstract]2023 Apr;44(4):726-740. PMID: 36216897
Oridonin purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2023 Apr;44(4):726-740. [Abstract]
Oridonin (Ori; 5-20 mg/kg; ip). The infarct volume was determined by conducting TTC staining at 1 d after reperfusion. Representative TTC-stained brain slices of different groups are shown.
Oridonin purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2023 Apr;44(4):726-740. [Abstract]
Oridonin (Ori; 5-20 mg/kg; ip). The expression levels of Bax, Bcl-2, mitochondrial Cyto-C, cytoplasmic Cyto-C, caspase-3 and cleaved caspase-3 were measured by Western blot analysis in the ipsilateral brain region at 1 d after reperfusion.
-
Phytomedicine
2024 Apr:126:155426. PMID: 38367425 -
Phytomedicine
Helenine blocks NLRP3 activation by disrupting the NEK7-NLRP3 interaction and ameliorates inflammatory diseases. [Abstract]2024 Jan:122:155159. PMID: 37931457 -
Phytother Res
Oridonin interrupts cellular bioenergetics to suppress glioma cell growth by down-regulating PCK2. [Abstract]2021 May;35(5):2624-2638. PMID: 33438793 -
Cell Mol Life Sci
Dual phosphorylation of glycogen synthase kinase 3β differentially integrates metabolic programs to determine T cell immunity across vertebrates. [Abstract]2025 May 28;82(1):218. PMID: 40434714
Oridonin purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 May 28;82(1):218. [Abstract]
CD3/CD28 mAbs-stimulated lymphocytes were treated with AKT inhibitor Oridonin (10 μM) or not. Western blot showing the expression of indicated molecules at 3 h.
-
Cell Mol Life Sci
2021 Dec 31;79(1):27. PMID: 34971423
Oridonin purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2021 Dec 31;79(1):27. [Abstract]
Time-dependent PHGDH inhibition. Samples of 200 nM PHGDH were pre-incubated with 1 μM Oridonin for the indicated times, and then PHGDH activity was monitored for 5 h. The time line is shown above. Black arrow indicates the start of the reaction. The data are normalized to the 5 h reading of the ‘0 min’ pre-incubated enzyme.
-
Anal Chim Acta
An exonuclease protection and CRISPR/Cas12a integrated biosensor for the turn-on detection of transcription factors in cancer cells. [Abstract]2021 Jun 22:1165:338478. PMID: 33975701 -
Biochem Pharmacol
Oridonin combined with cisplatin synergistically induces apoptosis by activating the NOXA-BCL2 axis in esophageal squamous cell carcinoma. [Abstract]2025 Apr 16:116953. PMID: 40250733 -
Biochem Pharmacol
NEK7 mediated assembly and activation of NLRP3 inflammasome downstream of potassium efflux in ventilator-induced lung injury. [Abstract]2020 Jul;177:113998. PMID: 32353421 -
Drug Des Devel Ther
2022 Dec 20:16:4311-4323. PMID: 36573068 -
Eur J Pharmacol
Oridonin regulates pituitary-derived folliculostellate cells apoptosis via the p38 MAPK/p53 signalling pathway. [Abstract]2026 Mar 28:1019:178664. PMID: 41724459 -
Eur J Pharmacol
Oridonin ameliorates hyperglycemia-induced bladder injury by promoting AMPK/PINK1/Parkin-mediated mitophagy. [Abstract]2026 Feb 15:1015:178559. PMID: 41548681 -
Int Immunopharmacol
Oridonin regulates the polarized state of Kupffer cells to alleviate nonalcoholic fatty liver disease through ROS-NF-κB. [Abstract]2021 Dec;101(Pt B):108290. PMID: 34717194 -
Drug Dev Res
2024 Sep;85(6):e22251. PMID: 39188035 -
Calcif Tissue Int
Oridonin Attenuates Thioacetamide-Induced Osteoclastogenesis Through MAPK/NF-κB Pathway and Thioacetamide-Inhibited Osteoblastogenesis Through BMP-2/RUNX2 Pathway. [Abstract]2023 Jun;112(6):704-715. PMID: 37032340 -
Biophys J
2026 Mar 3;125(5):1247-1256. PMID: 41578642 -
Front Biosci (Landmark Ed)
Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling. [Abstract]2023 Sep 6;28(9):195. PMID: 37796705 -
-
Dev Comp Immunol
Oridonin inhibits SGIV infection by regulating glycolipid metabolism and inflammatory response. [Abstract]2025 Jan 21:105324. PMID: 39848352 -
Dev Comp Immunol
Akt1/mTORC1 signaling modulates adaptive immune response of Nile tilapia by promoting lymphocyte activation and proliferation. [Abstract]2021 Jun:119:104042. PMID: 33582106 -
Biomed Res Int
Oridonin Promotes Apoptosis and Restrains the Viability and Migration of Bladder Cancer by Impeding TRPM7 Expression via the ERK and AKT Signaling Pathways. [Abstract]2021 Jul 5:2021:4340950. PMID: 34285910 -
Biochem Biophys Res Commun
CD73-enriched extracellular vesicles reduce cyclooxygenase 2 (COX-2)-mediated inflammation in activated macrophages. [Abstract]2025 Oct 22:788:152845. PMID: 41135135 -
Biochem Biophys Res Commun
De Novo design of a humanized antiCD33 antibody-oridonin conjugate for acute myeloid leukemia therapy. [Abstract]2022 Nov 12:629:152-158. PMID: 36122452 -
-
Solvent & Solubility
DMSO : 62.5 mg/mL (171.50 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.71 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.71 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% 1-Methyl-2-pyrrolidinone 90% PEG300
Solubility: ≥ 5 mg/mL (13.72 mM); Clear solution
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
For the AKT kinase assay, the ADP-Glo™ Kinase Assay Kit is used. Active AKT1 or AKT2 kinase and inactive GSK-3β as substrate are mixed by 1× reaction buffer and then added to a white 96-well plate. Pure ATP provided in the kit is serially diluted obtain a final concentration of 0, 1, 10, 50, and 100 μM. GSK-3β is added to reach a final concentration of 2.5, 5, 10 or 20 μM and DMSO is used as a control. The mixed solution is incubated at room temperature and luciferase activity is measured using the Luminoskan Ascent plate reader[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cells are seeded (6×103 cells/well for KYSE70; 2.5×103 cells/well for KYSE410; 2×103 cells/well for KYSE450) in 96-well plates and incubated for 24 h and then treated with different amounts of Oridonin or vehicle. After incubation for 24, 48 or 72 h, cell proliferation is measured by the MTT assay. For anchorage-independent cell growth assessment, cells (2.5, 5 or 10 μM Oridonin) suspended in complete medium are added to 0.3% agar with vehicle, 2.5, 5 or 10 μM Oridonin in a top layer over a base layer of 0.5% agar with vehicle, 2.5, 5 or 10 μM Oridonin. The cultures are maintained at 37°C in a 5% CO2 incubator for 3 weeks and then colonies are visualized under a microscope and counted using the Image-Pro Plus software program[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[2]
Breast cancer cells are harvested and resuspended in 40% Matrigel-Basement Membrane Matrix, LDEV-free, and then injected (100 μL per site) into the fourth pair of mammary fat pads of nude mice (CrTac: NCr-Foxn1nu). Tumors are measured in two dimensions using manual calipers. Tumor volume is calculated using the formula: Volume = 0.5 × length × width × width. Tumor volume is measured every 2-3 days. Upon harvesting, tumors are fixed in formalin overnight and then in 70% ethanol for histopathology analysis. Mice are treated with Oridonin (15 mg/kg) in 1% Pluronic F68 or vehicle (1% Pluronic F68) daily by intraperitoneal (IP) injection. BEZ235 is reconstituted 1:9 in 1-methyl-2 pyrolidone and polyethylene glycol 300 (PEG300) Mice are treated with this compound formulation at 45 mg/kg daily (QD) by oral gavage[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (291 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Song M, et al. Targeting AKT with oridonin inhibits growth of esophageal squamous cell carcinoma in vitro and patient derived xenografts in vivo. Mol Cancer Ther. 2018 Apr 25. pii: molcanther.0823.2017. [Content Brief]
[2]. Sun B, et al. Oridonin inhibits aberrant AKT activation in breast cancer. Oncotarget. 2018 Feb 1;9(35):23878-23889. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7440 mL | 13.7201 mL | 27.4401 mL | 68.6003 mL |
| 5 mM | 0.5488 mL | 2.7440 mL | 5.4880 mL | 13.7201 mL | |
| 10 mM | 0.2744 mL | 1.3720 mL | 2.7440 mL | 6.8600 mL | |
| 15 mM | 0.1829 mL | 0.9147 mL | 1.8293 mL | 4.5734 mL | |
| 20 mM | 0.1372 mL | 0.6860 mL | 1.3720 mL | 3.4300 mL | |
| 25 mM | 0.1098 mL | 0.5488 mL | 1.0976 mL | 2.7440 mL | |
| 30 mM | 0.0915 mL | 0.4573 mL | 0.9147 mL | 2.2867 mL | |
| 40 mM | 0.0686 mL | 0.3430 mL | 0.6860 mL | 1.7150 mL | |
| 50 mM | 0.0549 mL | 0.2744 mL | 0.5488 mL | 1.3720 mL | |
| 60 mM | 0.0457 mL | 0.2287 mL | 0.4573 mL | 1.1433 mL | |
| 80 mM | 0.0343 mL | 0.1715 mL | 0.3430 mL | 0.8575 mL | |
| 100 mM | 0.0274 mL | 0.1372 mL | 0.2744 mL | 0.6860 mL |